# Marcia S. Brose

Source: https://onco.cc/people/marcia-brose/  
OnCo record `marcia-brose` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led DECISION, the trial that made sorafenib the first approved targeted drug for radioiodine-refractory thyroid cancer.

## Summary

Marcia Brose was principal investigator of DECISION, the phase 3 trial that showed sorafenib doubles progression-free survival in radioiodine-refractory differentiated thyroid cancer and became the first targeted therapy approved for the disease in 40 years. She has led cabozantinib (COSMIC-311) and RET-inhibitor trials in thyroid cancer and chairs medical oncology at Jefferson.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: thyroid; targeted-therapy
- Role: Chair of Medical Oncology, Sidney Kimmel Cancer Center at Jefferson Health
- Specialisms: Thyroid cancer; Kinase inhibitors; Precision oncology; Head and neck cancer

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Brose%20MS%5BAuthor%5D%20thyroid%20sorafenib%20OR%20cabozantinib

## Connected records

- cancers: [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- institutions: [Sidney Kimmel Comprehensive Cancer Center at Jefferson Health](https://onco.cc/institutions/jefferson-kimmel/)
- trials: [DECISION](https://onco.cc/trials/decision-sorafenib/)

---
JSON: https://onco.cc/api/v1/entities/marcia-brose.json